GSK successfully fights against the gender pay gap
UK legislation came into effect in April 2017 requiring companies to share data showing the difference in average pay between its male and female employees. GSK is a member of the 30% Club gender campaign that aims to achieve 30% female representation in senior management within FTSE 100 companies by 2020. .
GlaxoSmithKline's U.S. price increases continuously outpace inflation
Drugs can keep millions healthy and save as many lives. Their consumption can prevent economic misery to families and humanity at large. Pharmaceutical companies can contribute to better health and well being by making drugs more accessible, not only in low- and middle-income countries (LMIC) but also in regions where poverty is overlooked as in the United States1 where prescription drug prices continually rank among the most expensive in the world2, p.1.
Setting the tone for gender balance in leadership
There is no doubt that women's economic participation and leadership in business is essential to drive business performance, as well as to advance corporate sustainability and increase global GDP. Still, Britain’s biggest public companies have a long way to go when it comes to achieving gender equality in leadership. Around two-thirds of all available roles still going to men and only six women held the top CEO position across the 100 biggest companies .
GlaxoSmithKline’s effort in waste management
Pharmaceutical consumption continues to grow constantly. As a result, the environment becomes more and more contaminated with pharmaceutical waste substances and their products. The pharmaceutical waste management becomes one of the most complex sustainability issues faced in the day-to-day world.
Exploitative pricing for vaccines in developing countries undermines efforts in global health
As part of its commitment to fight global health issues, particularly in developing countries, GSK states it aims to research and provide low prices for vaccines, find new ways to fight antibiotic resistance and is one of the few companies researching treatments and vaccines for infectious diseases such as TB, malaria and HIV.  In an article from 2016, it has reiterated its commitment to provide low prices for vaccines for refugees and contribute to global health security.